全球全基因组和外显子组测序市场 – 行业趋势和 2030 年预测

全基因组和外显子组测序市场分析和规模

推动全球全外显子组测序市场的关键因素包括临床诊断应用的增加和对罕见疾病诊断需求的不断增长、基因组学和下一代测序研发的增加以及对个性化医疗的需求不断增长。例如，2022 年 3 月发表在《英国医学杂志》上的一篇文章报道称，全外显子组测序可用于高度筛选的患者，以常规诊断罕见的儿童遗传病。文章还说，下一代测序可以以低得多的成本快速测序数百或数千个基因。由于外显子组测序的好处，预计研究市场将在预测期内增长。

此外，个性化医疗的日益普及预计将为预测期内全基因组和外显子组测序市场的增长提供潜在机会。

Data Bridge Market Research 分析称，全基因组和外显子组测序市场在 2022 年为 10.9922 亿美元，到 2030 年可能达到 47.1986 亿美元，预计在预测期内的复合年增长率为 21.20%。这表明市场价值。由于对产品的需求不断增长，“医院和诊所”在整个基因组和外显子组测序市场的终端用户部分占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

The whole genome sequencing helps to provide rich information regarding single nucleotide, structural, or copy number variants, while exome sequencing often makes more sense when time or resources are limited. Exome sequencing is also known as whole exome sequencing (WES), and is a genomic procedure for sequencing all of the protein-coding regions of genes in a genome.

Global Whole Genome and Exome Sequencing Market Dynamics

Drivers

• Increasing prevalence of cancer

The most major element driving this market's growth is the rise in cancer incidence and expanding uses of next-generation sequencing in cancer research. This is attributable to the increased adoption of the next-generation sequencing for the treatment of cancer across the globe. People are now increasingly adopting these therapies for treatment as they are more effective and have low side effects, which is boosting the growth of the market significantly. Researchers are using these techniques to uncover genetic variations associated with diseases, personalized medicine, and other critical areas of study.

• Rise in the acceptance of next-generation sequencing methods

The total market is being driven by a growth in acceptability of next-generation sequencing approaches for the prediction, treatment, and monitoring of a variety of chronic diseases, such as cancer. Moreover, the integration of genomic sequencing into clinical and diagnostic settings has expanded the market. It is being used for the diagnosis of various genetic disorders and as a screening tool in prenatal and new-born care.

• Low cost and high speed of the technology

The cost of sequencing has significantly decreased over the years, making it more accessible to researchers, clinicians, and patients. This cost reduction has widened the market's reach and increased adoption. Thus, when compared to whole genome sequencing, whole exome sequencing has a lower cost which will further anticipated to propel the growth of the market.

Opportunity

• Technological advancement of therapies for the treatment

Continuous improvements in sequencing technologies and bioinformatics tools have enhanced the speed, accuracy, and efficiency of whole genome and exome sequencing. This, in turn, will extend profitable opportunities for the market players in the forecast period of 2023 to 2030 by enabling more comprehensive and cost-effective sequencing.

Moreover, it is anticipated that the market for whole genome and exome sequencing will exhibit lucrative growth with the ongoing developments in genomic research have expanded the applications of whole genome and exome sequencing.

Restraint/Challenge

• Dearth of skilled personnel

On the other hand, the dearth of skilled professionals and high reliability on grants is further projected to impede the growth of the whole genome and exome sequencing market in the targeted period. Moreover, the ethical and legal concerns regarding to whole exome sequencing might further challenge the growth of the whole genome and exome sequencing market in the forecast period of 2023-2030.

This whole genome and exome sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the whole genome and exome sequencing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2020, The "Genome India Project" was started by the Department of Biotechnology (DBT) (GIP). The goal of the initiative is to collect 10,000 genetic samples from Indian residents in order to create a reference genome. Precision health, rare genetic illnesses, the mutation spectrum of genetic and complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research are some of the areas of attention for this project

Global Whole Genome and Exome Sequencing Market Scope

The whole genome and exome sequencing market is segmented on the basis of technology, products and services, applications and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Others

Products and Services

• Products
• Systems
• Kits
• Services
• Sequencing Services
• Data Analysis Services
• Others

Applications                                                         

• Diagnostics
• Cancer
• Monogenic Disorders
• Diabetes
• Drug Discovery and Development
• Personalized Medicine
• Agriculture and Animal Research
• Others

End user

• Research Center
• Academic and Government Institutions
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Others

Global Whole Genome and Exome Sequencing Market Regional Analysis/Insights

The whole genome and exome sequencing market is analyzed, and market size insights and trends are provided by country, technology, products and services, applications, and end users, as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Brazil, Argentina, rest of South America, Germany, France, Italy, U.K., Belgium, Spain, Russia, Turkey, Netherlands, Switzerland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, U.A.E., Saudi Arabia, Egypt, South Africa, Israel, and rest of Middle East and Africa.

North America is expected to dominate the whole genome and exome sequencing market due to the rise in the incidence of genetic and chronic disorders, including cancer. Furthermore, the growing geriatric population and increasing demand for targeted and personalized medicine will further boost the growth of the whole genome and exome sequencing market in the region during the forecast period.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to the regular government funding. Moreover, the growing numbers of conferences regarding the whole exome sequencing technique is further anticipated to propel the growth of the whole genome and exome sequencing market in the region in the coming years.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

全基因组和外显子组测序市场还为您提供每个国家/地区资本设备医疗保健支出增长、全基因组和外显子组测序市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对全基因组和外显子组测序市场的影响的详细市场分析。数据涵盖 2010-2020 年的历史时期。

竞争格局和全基因组和外显子组测序市场份额分析

全基因组和外显子组测序市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全基因组和外显子组测序市场的关注有关。

全基因组和外显子组测序市场的一些主要参与者包括：

• DIGIRAD CORPORATION（美国）
• 东软集团 (中国)
• 佳能医疗系统株式会社（日本）
• SurgicEye GmbH（德国）
• Mediso Ltd.（匈牙利）
• CMR Naviscan。（美国）
• DDD-Diagnostic A/S（丹麦）
• Absolute Imaging Inc.（加拿大）
• Bartec Technologies Ltd.（英国）
• BCL X-Ray Canada Inc.（加拿大）
• TTG Imaging Solutions, LLC（美国）
• Mirion Technologies (Capintec), Inc.（美国）
• LANDAUER（美国）
• Ashby Gorman Baker Ltd.（比利时）
• Lucerno Dynamics, LLC.（美国）
• Berthold Technologies GmbH & Co.KG（德国）
• Incom, Inc.（美国）
• 西门子（美国）
• Koninklijke Philips NV（荷兰）
• Spectrum Dynamics Medical（瑞士）

SKU-68273